GC Cell Partners with DAAN Biotherapeutics for Tumor Antigen-Specific Antibody Sequence
Shots:
- DAAN Biotherapeutics & GC Cell have entered into an exclusive technology transfer agreement for tumor antigen-specific antibody sequence
- As per the agreement, DAAN has granted GC Cell exclusive rights to use its antibody sequence, which targets a protein highly overexpressed in major solid tumors, for research & development of CAR-T & CAR-NK therapies
- Financial terms of the agreement remain undisclosed but incl. upfront payment along with development & commercial milestones, plus sales-based royalties to DAAN Biotherapeutics
Ref: Prnewswire | Image: DAAN Biotherapeutics & GC Cell
Related News:- Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
